Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Als save search
FDA Reverses Course on NDA Submission for Amylyx ALS Drug
Published: 2021-09-15 (Crawled : 18:00) - biospace.com/
BCLI | $0.5845 13.65% 790K
|
Health Technology
|
| O: 1.91%
H: 18.75%
C: 10.31%
fda drug submission als
Alector Announces First Participant Dosed in Phase 2 Study Evaluating AL001 in Amyotrophic Lateral Sclerosis (ALS)
Published: 2021-09-09 (Crawled : 21:00) - biospace.com/
ALEC | $4.99 -1.97% 150K
|
Health Technology
|
| O: 0.39%
H: 7.85%
C: 3.16%
phase 2 sclerosis al001 als
Denali Therapeutics Announces Initiation of Phase 1b Study of EIF2B Activator DNL343 in ALS— Investigational EIF2B activator approach has potential to be a first-in-class treatment for ALS —
Published: 2021-09-09 (Crawled : 14:00) - biospace.com/
DNLI | $16.1 -3.01% 280K
|
Health Technology
|
| O: -0.11%
H: 2.54%
C: -0.3%
treatment phase 1 potential phase 1b als phase 2b
Clene Completes Final Patient Visit in Phase 2 RESCUE-ALS Study: Topline Data Readout Expected Q4 2021
Published: 2021-09-09 (Crawled : 11:00) - globenewswire.com
CLNN S | $0.3248 -1.55% 420K
|
|
| O: 1.3%
H: 1.93%
C: 0.9%
phase 2 topline als
ReShape Lifesciences™ Appoints Al Diaz as Vice President of Operations and Research and Development
Published: 2021-08-31 (Crawled : 12:15) - globenewswire.com
RSLS | $0.1707 15K
|
Manufacturing
|
| O: -1.64%
H: 4.69%
C: 4.69%
research als
MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 32nd International Symposium on ALS/MND
Published: 2021-08-30 (Crawled : 11:00) - globenewswire.com
MNOV | $1.4 6.4K
|
Health Technology
|
| O: -0.13%
H: 2.36%
C: 0.26%
presentation als mn-166 symposium
Cytokinetics Announces Start of COURAGE-ALS, a Phase 3 Clinical Trial of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis
Published: 2021-08-02 (Crawled : 12:00) - globenewswire.com
CYTK | $66.445 -0.83% 480K
|
Health Technology
|
| O: 2.52%
H: 1.57%
C: -3.03%
sclerosis phase 3 trial als
Mi barrio sin residuos llega al área metropolitana del Valle de Aburrá.
Published: 2021-07-21 (Crawled : 04:00) - coca-colafemsa.com
PKX | News | $70.665 0.81% 13K
|
Non-Energy Minerals
|
| O: 0.78%
H: 0.78%
C: 0.77%
als
Scott+Scott Attorneys at Law LLP Announce a Notice of Proposed Settlement of Class Action in St. Lucie County Fire District Firefighters' Pension Trust v. Southwestern Energy Co., et al.
Published: 2021-07-19 (Crawled : 14:15) - prnewswire.com
SWN | $7.375 1.31% 2.6M
|
Energy Minerals
|
| O: -3.33%
H: 2.8%
C: -1.29%
energy als
Aptorum Group Announces Further Positive Interim Results of the Phase 1 Clinical Trial of ALS-4 Targeting Staphylococcus aureus
Published: 2021-07-12 (Crawled : 13:00) - biospace.com/
APM | $5.7 6.15% 16K
|
Health Technology
|
| O: 4.3%
H: 0.0%
C: -5.08%
phase 1 positive results trial phase 2 phase 3 als staphylococcus aureus
Hill International to Provide Project Management Oversight for the 5-Star Anantara Resort Hotel in Ras Al Khaimah
Published: 2021-07-08 (Crawled : 13:00) - globenewswire.com
HIL | $3.39 0.3%
|
Industrial Services
|
| O: -0.81%
H: 0.0%
C: -0.82%
hotel als
Mitsubishi Tanabe Pharma America Announces EXSERVAN™ (riluzole) is Now Available in the U.S. for the Treatment of ALS
Published: 2021-06-30 (Crawled : 18:00) - biospace.com/
AQST | $4.405 -2.11% 850K
|
Health Technology
|
| O: -0.25%
H: 0.25%
C: -0.75%
treatment als riluzole pharma
Clene to Host Expert Perspectives Webinar on Cellular Energetic Failure and the Unmet Medical Needs in ALS and MSWebinar to take place on Wednesday, July 14, 2021 at 4:30 p.m. ET
Published: 2021-06-30 (Crawled : 13:00) - biospace.com/
CLNN S | $0.3248 -1.55% 420K
|
|
| O: -0.27%
H: 2.91%
C: 2.37%
als
Clene to Host Expert Perspectives Webinar on Cellular Energetic Failure and the Unmet Medical Needs in ALS and MS
Published: 2021-06-30 (Crawled : 11:00) - globenewswire.com
CLNN S | $0.3248 -1.55% 420K
|
|
| O: -0.27%
H: 2.91%
C: 2.37%
als
Genmab Announces that Janssen has Received European Marketing Authorizations for DARZALEX® (daratumumab) Subcutaneous Formulation, Including for the Treatment of Patients with Newly Diagnosed Light-chain (AL) Amyloidosis
Published: 2021-06-22 (Crawled : 14:15) - globenewswire.com
JNJ | News | $146.39 0.45% 1.8M
|
Health Technology
|
| O: -0.08%
H: 0.2%
C: -0.05%
GMAB | $28.805 1.68% 80K
|
Health Technology
|
| O: 0.09%
H: 0.63%
C: 0.53%
treatment europe authorized als
Caelum and Alexion Present Additional Phase 2 Data Reinforcing Safety and Tolerability of CAEL-101 in AL Amyloidosis at the European Hematology Association Congress 2021
Published: 2021-06-11 (Crawled : 11:00) - biospace.com/
FBIO | $1.775 -1.93% 120K
|
Health Technology
|
| O: 3.49%
H: 0.9%
C: 0.9%
AZN | $68.3 -0.09% 2M
|
Health Technology
|
| O: 0.49%
H: 0.03%
C: -0.61%
phase 2 europe als
Block & Leviton LLP Announces a Notice of Pendency and Proposed Settlement of Class Action in the Tomaszewski v. Trevena, Inc., et al
Published: 2021-06-07 (Crawled : 14:15) - prnewswire.com
TRVN | $0.349 -4.65% 120K
|
Health Technology
|
| O: 1.67%
H: 8.74%
C: 7.1%
als
Incyte and MorphoSys Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCL
Published: 2021-06-04 (Crawled : 20:00) - biospace.com/
XNCR | $18.65 -1.58% 130K
|
Health Technology
|
| O: 0.38%
H: 1.25%
C: -0.76%
MOR | $17.96 -0.5% 72K
|
Health Technology
|
| O: 3.74%
H: 3.11%
C: 2.76%
INCY | $52.45 -0.7% 530K
|
Health Technology
|
| O: 0.33%
H: 1.54%
C: 0.19%
treatment phase 2 results als
Bassist and Producer Al Carty Leverages ClearOne Aura® Home Office Solution to Adapt to a Changing Music Industry
Published: 2021-06-02 (Crawled : 13:15) - globenewswire.com
CLRO | $0.981 1.35% 25K
|
Electronic Technology
|
| O: -1.67%
H: 2.13%
C: 1.7%
als
Aptorum Group Announces Positive Interim Phase I Clinical Trial Progress for ALS-4 Targeting Staphylococcus aureus and Positive Pre-IND Progress for SACT-1 Targeting Neuroblastoma
Published: 2021-05-24 (Crawled : 13:00) - biospace.com/
APM | $5.7 6.15% 16K
|
Health Technology
|
| O: 9.75%
H: 35.53%
C: 7.2%
positive trial als staphylococcus aureus
Gainers vs Losers
| 76% | 24% |
Top 10 Gainers
AGBA | News | $1.22 205.0% 86M
|
Finance
EGOX | $0.054 50.0% 290M
|
CHRO | $1.66 35.51% 70K
|
n/a
INDO | $5.43 33.09% 10M
|
Energy Minerals
NVFY | $2.71 28.44% 31M
|
Consumer Durables
ZCMD | $1.86 28.28% 29M
|
Commercial Services
RWOD | $10.08 26.05% 5.6M
|
n/a
HUSA 4 | $2.07 23.95% 2.1M
|
Energy Minerals
TPET | $0.4001 22.02% 35M
|
n/a
SRFM 4 | $0.6 21.29% 850K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.